Astrocyte Pharmaceuticals reports the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke.
The manuscript describes the results of pre-clinical studies using AST-004, Astrocyte’s lead drug candidate, for the treatment of stroke.